CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 6967 result(s)

Secukinumab (Cosentyx)

Last Updated: January 21, 2016
Result type: Reports
Product Line: Common Drug Review
Generic Name: Secukinumab
Indications: Arthritis, psoriatic

  • Brand Name: Cosentyx
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0476-000
  • Project Status: Complete
  • Submission Type: New

Sapropterin dihydrochloride (Kuvan)

Last Updated: January 4, 2016
Result type: Reports
Product Line: Common Drug Review
Generic Name: Sapropterin dihydrochloride
Indications: Phenylketonuria (PKU)

  • Brand Name: Kuvan
  • Manufacturer: BioMarin Pharmaceutical (Canada) Inc.
  • Project Number: SR0472-000
  • Project Status: Complete
  • Submission Type: Resubmission

pCODR Clinician Input and Feedback

Published on: August 9, 2018
Result type: General Content

The CADTH pan-Canadian Oncology Drug Review (pCODR) undertakes rigorous, objective reviews of cancer drugs and provides funding recommendations to Canada’s provinces and territories (except Quebec). Funders use this information as one element of their decision-making process to determine if a drug will be eligible for public reimbursement. ...